TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Symptomatic intracranial hemorrhage within 5 days
Endpoint domain: Adverse events/effects
Primary endpoint: Asymptomatic hemorrhagic transformation detected by brain imaging
Endpoint domain: Adverse events/effects
Primary endpoint: Favorable outcomes as measured by mRS scores at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Ability to explain correct interventions in a case study about VAW
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: chronic postoperative pain level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients requiring oral pain medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of climacteric complaints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effects on bone metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonic fermentation (CF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in subjective symptoms after exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemoglobin mean concentration increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ferritin concentration increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Nutritional depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Affected limb use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ARA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost estimates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: employment income
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: poverty status
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Constant‐Murley Shoulder Score (CMS) pain subscore improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypercarotenemia prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum retinyl esters concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum PLP concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in Zernike term Z (3) (1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in Zernike term Z (4) (-2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in Zernike term Z (5) (-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gustatory sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tobacco abstinence at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hazard of acquisition of high‐viral load infections for HPV‐16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Hazard of acquisition of high‐viral load infections for HPV‐18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 6-month risk of HPV persistence for HPV‐16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 6-month risk of HPV persistence for HPV‐18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction of PAS extent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of intraocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine efficacy against HPV-16/18 persistent infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Geometric mean titers against HPV-16 and HPV-18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Health-related quality of life (HQOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: liver enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inferior vena cava enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: portal enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain related disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fear-avoidance beliefs
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: incident cases of visually significant AMD
Endpoint domain: Mortality/survival
Primary endpoint: Reported dry mouth
Endpoint domain: Adverse events/effects
Primary endpoint: Moderate/severe dry mouth
Endpoint domain: Adverse events/effects
Primary endpoint: Withdrawal from study due to dry mouth
Endpoint domain: Adverse events/effects
Primary endpoint: Spinal canal dimension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neuropathy score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: perceived clinical condition improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Amount of iv morphine used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased mortality risk associated with gram-negative intestinal colonization
Endpoint domain: Mortality/survival
Primary endpoint: Interest in living donation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pursuit of living donation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: recurrent ischemic stroke at 90 days
Endpoint domain: Mortality/survival
Primary endpoint: fewer hospital visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: fewer symptom relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reductions in CHD risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvements in HRQOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvements in exercise capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total yearly lengthening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: regional cerebral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Participant satisfaction with the treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total amount of glucose infused (G(tot))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum glucose infusion rate (GIR; R(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average cost of hospital at home versus hospital treatment
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: fat mass gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bone mineral content deposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary airway resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: K‐ras point mutation frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Survival of patients with mutated K‐ras tumors
Endpoint domain: Mortality/survival
Primary endpoint: MIDAS values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic Blood Pressure Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic Blood Pressure Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: acute rejection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in physical functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Post-void residual (PVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: International Prostate Symptom Score (IPSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: days with little itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative calcium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative magnesium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of abnormal values for calcium, potassium, phosphorus and base deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diastolic Blood Pressure (BP) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulse Pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Eating of exposed foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safer pedestrian behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: entering safe traffic gaps more quickly
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fewer hits/close calls
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of subacute thrombosis (SAT)
Endpoint domain: Adverse events/effects
Primary endpoint: post-test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seizure outcome after 1 year of AED treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean 24-h ambulatory blood pressure (ABP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CSP onset and end latencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Motor and sensory nerve conduction velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hemoglobin A1c reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase of liver transaminases (grade 1/2)
Endpoint domain: Adverse events/effects
Primary endpoint: procollagen production rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: post-exercise levels of lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: post-exercise levels of creatine kinase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: post-exercise levels of testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: dietary diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: higher visual analogue scale scores of pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced pressure pain thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased difficulty in performing the ASLR
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of patients remaining frequent exacerbators at year 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in severe exacerbations leading to hospitalization/death
Endpoint domain: Mortality/survival
Primary endpoint: maximum water sorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: solubility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAP incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HME resistance after 24 hrs of use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunoreactive endothelin plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Vibratory sensations of the peripheral nerves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Edge restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Late edge lumen loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: percentage change in triglyceride serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: non-cancer-related survival
Endpoint domain: Mortality/survival
Primary endpoint: treatment rating as excellent/good
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: decrease in haemoglobin (≥1 g/dl)
Endpoint domain: Adverse events/effects
Primary endpoint: mean drop in hemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: transfusion requirement
Endpoint domain: Adverse events/effects
Primary endpoint: postprandial glucose response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: visual measure of vaginal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of satisfaction with pain control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cognitive functioning change
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 3-year mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: composite of death or strokes
Endpoint domain: Mortality/survival
Primary endpoint: Mean intraoperative heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean time of the first analgesic request
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative tramadol consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 2-year TLR or restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Achievement of clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Teeth eruption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in dentinal hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean gap width (IGW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hybrid layer thickness (HLT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase of IGF‐I
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary excretion rates of nitrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary excretion rates of cyclic GMP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of staff-resident interactions
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: total hair yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: transection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: graft:hair ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in SCORAD from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4 T‐lymphocyte counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4/CD8 T‐cell ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PD‐1 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Urinary calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary oxalate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary citrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean number of hot flushes per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Composite Score (CCS) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Global Operative Assessment of Laparoscopic Skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Structured Assessment of Technical Skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operative Performance Rating System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median percentage reductions in plasma cytokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in PGAxBSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of days stably housed
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: duration of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance correlation coefficient for normalized oxycodone urine drug levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reactionary dentine barrier formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: narrowing of root canals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: histological evidence of resorption of reactionary dentine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in meibomian gland dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Improvement in ocular symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Acute and late ≥G3 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Complete resolution rates of otitis media with effusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BCVA ≥20/40
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BCVA letter score improvement ≥15
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of edema (CFT ≤250 μm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily insulin dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: frequency of hypoglycemic events
Endpoint domain: Adverse events/effects
Primary endpoint: incision healing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Social support levels
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Health beliefs total score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: GP visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sensitivity for diagnosis of appendicitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity for diagnosis of appendicitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic confidence in the diagnosis of appendicitis
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Local anesthetic toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erector spinae muscle flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft occlusion risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: unfavourable neurologic outcome (GOSe ≤ 4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Approval of aggression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Dating attitudes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: DV perpetration and victimization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spasticity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait speed enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost savings per child treated
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: number of hypoglycaemic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes